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Abstract
Background: Osteogenesis imperfecta, fibrous dysplasia/McCune-Albright syndrome and X-linked
hypophosphatemia are three rare musculoskeletal diseases characterised by bone deformities, frequent fractures
and pain. Little high-quality research exists on appropriate treatment and long-term management of these
conditions in adults. This is further worsened by limited research funding in rare diseases and a general mismatch
between the existing research priorities and those of the patients. This partnership adopted the James Lind Alliance
approach to identify the top 10 research priorities for rare musculoskeletal diseases in adults through joint patient,
carer and healthcare professional collaboration.
Results: The initial survey for question collection recruited 198 respondents, submitting a total of 988 questions.
77% of the respondents were patients with a rare musculoskeletal disease. Following out-of-scope question
exclusion, repeating query grouping and scientific literature check for answers, 39 questions on treatment and
long-term management remained. In the second public survey, 220 respondents, of whom 85% were patients with
a rare musculoskeletal disease, their carers, relatives or friends, prioritised these uncertainties, which allowed
selection of the top 25. In the last stage, patients, carers and healthcare professionals gathered for a priority setting
workshop to reach a consensus on the final top 10 research priorities. These focus on the uncertainties surrounding
appropriate treatment and holistic long-term disease management, highlighting several aspects indirect to
abnormal bone metabolism, such as extra-skeletal symptoms, psychological care of both patients and their families
and disease course through ageing.
Conclusions: This James Lind Alliance priority setting partnership is the first to investigate rare bone diseases. The
priorities identified here were developed jointly by patients, carers and healthcare professionals. We encourage
researchers, funding bodies and other stakeholders to use these priorities in guiding future research for those
affected by rare musculoskeletal disorders.
Keywords: James Lind Alliance, Priority setting partnership, Fibrous dysplasia/McCune-Albright syndrome, X-linked
hypophosphatemia, Osteogenesis imperfecta, Rare musculoskeletal diseases, Research priorities, Patient and public
involvement, Research mismatch
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Background
Fibrous dysplasia/McCune-Albright Syndrome (FD/
MAS), X-linked hypophosphatemia (XLH) and osteo-
genesis imperfecta (OI) are rare genetic musculoskeletal
disorders characterised by bone pain, lesions and de-
formities as well as a number of other extra-skeletal
symptoms and complications. Limited treatment options
are available for these conditions and wide gaps of
knowledge persist in natural disease history, long-term
risks, disease management and quality of life in those af-
fected. Consequently, there is little awareness amongst
healthcare professionals on the diagnosis and manage-
ment of these disorders, which is further complicated by
natural variability in clinical presentation and disease
burden [1–3]. Therefore, it may take years for some pa-
tients before appropriate diagnosis is given and high-
quality specialist care is accessed.
These issues are worsened by limited research funding
in rare diseases and the apparent detachment of existing
research efforts and knowledge base from patient, carer
and healthcare professional research priorities [4, 5].
However, over the last three decades patient involve-
ment in research has been increasingly recognised and
valued in terms of providing needs-led research prior-
ities for attaining best patient care [6–8]. The James
Lind Alliance (JLA), hosted by the National Institute for
Health Research, is a non-profit initiative providing a
transparent, rigorous approach supervised by an impar-
tial JLA adviser which brings patients, carers and health-
care professionals together for a research priority setting
partnership (PSP) [9, 10]. Since its establishment in
2004, numerous PSPs have been carried out on a range
of disorders, further reaffirming marked differences be-
tween the priorities of researchers and those identified
within the PSPs [11, 12].
Several PSPs have been completed for common mus-
culoskeletal conditions [13–17], however none addressed
rare musculoskeletal disorders. This PSP applied the JLA
method to a group of rare musculoskeletal disorders in
adults – FD/MAS, XLH and OI, in order to identify the
most important research directions in diagnosis, treat-
ment and long-term management.
Methods
This PSP aimed to identify research uncertainties com-
mon to rare musculoskeletal disorders and related to
their treatment and long-term management. The rigor-
ous and transparent JLA PSP approach, outlined in Fig. 1,
involved patients, carers and healthcare professionals. It
was overseen by an impartial JLA adviser and a JLA pro-
ject manager to ensure equal and fair participant repre-
sentation. This partnership took place from December
2015 to November 2018.
Steering group formation
The steering group was assembled to oversee and lead the
PSP through its every stage. Fair representation of patients,
carers and healthcare professionals was ensured by includ-
ing both the patient representatives (n = 6) and healthcare
professionals (n = 5). As dictated by the JLA methodology,
pure researchers were excluded from the PSP process as
their voice is already represented by the majority of the
existing scientific literature [10]. The members of the steer-
ing group were asked to declare any competing interests.
The steering group committed to publicising the PSP
surveys and outcome through their connections to
stakeholders and relevant communities. In order to
gather appropriate patient and public involvement, the
PSP was conducted in collaboration with the following
patient support organisations and charities: Brittle Bone
Society, The Fibrous Dysplasia Support Society, XLH
Network, XLHUK and Genetic Alliance UK. Further-
more, the steering group supervised survey development
and data analysis, recruited appropriate individuals to
conduct an evidence search and participated in the final
priority setting workshop. The steering group ensured
that the PSP was inclusive and fair to all the participat-
ing groups and representatives, considering both the
practical and the methodological aspects of the project.
Fig. 1 Flowchart summarizing the rare musculoskeletal diseases in
adults PSP process
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Scope
This PSP focused on adult patients with XLH, OI or FD/
MAS, their carers and healthcare professionals. These
disorders were chosen because of the active patient
groups they have. The focus on adults, defined as aged
16 and above, aimed to capture adult patient underrep-
resentation in the current scientific knowledge base and
potential uncertainties arising during patient transition
from paediatric to adult services. The scope of this PSP
was defined to include uncertainties on treatment, long-
term management and diagnosis of the disorders. The
latter was recognised as a potentially challenging topic
to cover considering limited PSP resources. Thus, it was
agreed that the steering group would make most appro-
priate decisions on the use of such uncertainties depend-
ing on the responses received from the survey for
question collection. Lastly, the steering group agreed to
expand survey distribution to certain other countries
with similar standards of care, namely Spain, Italy,
France, Netherlands, Germany, Denmark and Norway,
in order to maximise the number of responses for these
rare disorders. Due to its limited resources, the PSP ac-
cepted survey responses applicable only to the UK
healthcare system and written in English.
Survey for question collection
The initial survey was designed to ask patients, their
carers and healthcare professionals for any questions
they had about one of the three rare disorders. It was
composed online using SurveyMonkey and as a PDF for
printing and local distribution to those unable to access
it online. Before its release, the steering group made sure
the survey was comprehensible for all potential respon-
dents, no matter their scientific background. The steer-
ing group members, collaborating patient support
organisations and charities used their contacts to dis-
seminate the survey via email, social media, newsletters,
blogs and websites. The survey collected basic demo-
graphic data, including respondent type (patient, carer
or clinician), name of the rare musculoskeletal disease
the patient has (XLH, FD/MAS or OI), gender and
country of residence, in addition to the free text answers
for the questions respondents had. The answers could
be submitted from March to July 2017.
Survey response categorisation and evidence search
Submitted questions were assessed for their relevance to
the scope of this PSP. They were omitted from the fur-
ther process if they were off-topic, too broad, unclear or
no scientific research was required to answer them. Fur-
thermore, questions specific to a non-UK healthcare sys-
tem were omitted as well. The remaining uncertainties
were grouped into overarching questions if repeated
across respondents. This stage of the PSP was performed
by an information specialist and was overseen by the
steering group to ensure clarity and accurate collation of
the questions.
In the next stage, the remaining uncertainties were
checked against the existing high-quality scientific evi-
dence, namely systematic reviews, clinical trials and
guidelines. Uncertainties that could be reliably answered,
i.e. the “unrecognised knowns”, were excluded from the
further PSP process. Some questions had limited scien-
tific literature to answer them and additional discussion
by the steering group determined whether they were in-
cluded in the further stages of the PSP. This produced
the longlist of questions.
Interim prioritisation survey
The aim of this survey was to prioritise the longlist of
questions and produce a shortlist for the final priority
setting workshop. The survey was composed online
using SurveyMonkey. It was piloted by the steering
group and distributed via the same channels as the first
survey. It collected basic demographic data from its re-
spondents (described in “Survey for question collection”)
and asked to select the ten most important questions
from the presented longlist, where their order was auto-
matically randomised for each participant. Then, the re-
spondent was able to rank the selected questions from
the most to least important. The answers could be sub-
mitted from April to May 2018.
The survey responses were used to create a prioritised
question longlist. In order to do so, four separate rank-
ings were produced according to the type of respondent:
1) FD/MAS, 2) OI, 3) XLH patients and carers as well as
4) healthcare professionals. The rankings were combined
to yield an overall ranking position for each question,
which ensured equal representation of the four groups
in the exercise. The top 25 questions were selected for
proceeding to the final priority setting workshop.
Priority setting workshop
Over the duration of a single day, the priority setting
workshop was designed to bring together patients, carers
and healthcare professionals in order to produce the top
10 research priorities from the shortlist of questions.
The participants (n = 18) were members of the steering
group and other representatives recruited via previously
used dissemination channels. Equal representation of pa-
tients, carers and healthcare professionals was ensured.
The workshop comprised several small group discus-
sions, where all participants were able to share their
views. This process allowed the group to reach a consen-
sus on the final top 10 research uncertainties. The JLA
adviser was present during the workshop to mediate the
discussion and ensure equal contribution of the partici-
pants. To guarantee transparency, those participating in
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the priority setting workshop were asked to declare any
competing interests. The event was held at Friends
Meeting House in London in June 2018.
Results
The summary of the PSP process is presented in Fig. 1.
The survey for question collection received 198 re-
sponses, gathering a total of 988 questions. Most respon-
dents identified as patients with one of the three rare
musculoskeletal disorders (77%), whilst others indicated
being carers, relatives or friends (11%), health and social
care professionals (11%) or representatives of organisa-
tions (1%).
Following the categorisation of survey results, 364
questions out of the 988 were identified as not relevant
to this PSP. Out of those, 186 did not require scientific
research to be answered, 65 inquired about healthcare
professional training and service access and 113 were
considered unclear, too broad or off-topic. The
remaining questions were grouped into overarching
questions if repeated, yielding a total of 41 questions.
These were checked against published high-quality re-
search evidence and two questions were identified as
“unrecognised knowns”, where sufficient scientific evi-
dence existed to reliably answer them:
1. Could diagnosis in adults be made faster and more
accurate e.g. through use of genetic or other
biomedical tests?
2. What is the optimal imaging technique for fibrous
dysplasia?
The remaining questions (n = 39) comprised the PSP
longlist. Thematically, questions addressed treatment
(n = 14), prognosis (n = 8), self-management (n = 3), sup-
port and care (n = 3), healthcare (n = 3) and prevention
(n = 1). Several other questions did not adhere to any of
these thematic groups (n = 7).
The longlist was prioritised via the interim prioritisa-
tion survey, where 220 submissions were received. Most
of the respondents were patients, carers, relatives or
friends (85%), whilst others were healthcare professionals
(14%) and representatives of organisations (1%). Most of
the respondents were female (83%) and from outside of
the UK (56%). The respondent ethnic group was white
by a large majority (94%). This prioritisation exercise
allowed the steering group to shortlist the top 25 re-
search uncertainties for the final stage of the PSP.
In the priority setting workshop, patients, carers and
healthcare professionals were able to discuss the shortlist
and reach a consensus on the final top 10 research pri-
orities, which are shown in Fig. 2. All questions received
from the survey of question collection, including those
classified as irrelevant to this PSP, as well as the full
longlist and shortlist are available on the rare musculo-
skeletal diseases in adults PSP website [18].
Discussion
Following the established JLA methodology, this priority
setting partnership identified the top 10 research uncer-
tainties for three rare metabolic bone disorders – OI,
XLD and FD/MAS. This was achieved with close and
continuous patient, carer and healthcare professional in-
volvement, ensuring research priority relevance for im-
proving disease treatment and long-term management.
The final 10 priorities addressed aspects of treatment,
natural disease history (prognosis), self-management,
support and care as well as prevention. The main over-
arching focus of these questions appears to be the need
for better understanding of rare metabolic bone disease
progression in adulthood and what treatments and man-
agement approaches provide most effective, long-term
symptom management.
This PSP is the first to investigate any metabolic bone
disorder. Furthermore, it addressed rare disease, which
out of over a hundred completed official and JLA-
associated partnerships thus far only few PSPs had done
before [19–22]. Previous scientific literature on XLD, OI
and FD/MAS has highlighted several of the questions
identified as the top 10 research priorities within this
project, namely the lack of scientific research on appro-
priate treatment outcomes, surgical interventions, dental
problem prevention, as well as benefits, side effects,
dosing and length of pharmacological therapies [1, 3,
23–25]. Furthermore, previous publications have identi-
fied the increasing importance of addressing disease
management aspects applicable to adults, as more pa-
tients progress into adulthood due to improved child-
hood therapies [3]. However, this work, to our
knowledge, is the first in the field to thoroughly describe
the research demand for better rare metabolic bone dis-
ease management in adults and highlight aspects import-
ant to patients that otherwise could have been
overlooked by research.
Of special note are the two “unrecognised knowns”
identified during this PSP, i.e. uncertainties expressed by
survey respondents that in fact can be answered confi-
dently by the existing research evidence. Whilst the
question on the optimal imaging technique was asked
only once, variations of the question about the diagnosis
were submitted on 10 separate occasions [18]. Even so,
as these questions were not included in the prioritisation
process, it remains unclear how relevant they are to the
patient, carer and healthcare professional groups overall.
Their presence might indicate an area of improvement
in the effective communication of knowledge to health-
care professionals, patients and their carers.
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Several aspects ensured the relevance and impact of
this PSP to the future research on rare metabolic
bone disorders. The adopted JLA approach, continued
guidance by the JLA adviser and involvement of all
relevant stakeholder groups assured adherence to an
established, rigorous and transparent process. Open
access of the full list of questions with unchanged
original respondent submissions upholds these qual-
ities in the result publication stage as well [18]. This
also allows stakeholders to investigate other research
priorities that did not reach the top 10. Furthermore,
even though this PSP focused on rare disorders, ad-
equate patient and carer involvement was achieved
through the efficient use of the steering group mem-
bers’ contacts and through collaboration with the pre-
viously mentioned patient organisations and charities,
allowing the PSP to reach participants from both the
UK and outside. In addition, we anticipate that the
strategy of investigating several related rare diseases
within a single PSP eased the recruitment of a larger
sample of participants. Finally, this PSP provided re-
search priorities that are formulated in a deliberately
broad fashion. It was previously reported that broader
treatment uncertainties are ranked higher in priori-
tisation exercises [16]. We expect that such is the
case because broader questions are applicable to more
people and, within this project, conditions, making
the potential answers more impactful for the overall
healthcare provision.
However, this work also carries a few limitations. The
survey respondent group was under-representative of
ethnic minorities and was mostly female. In addition,
most respondents were patients and comparatively few
carers and healthcare professionals responded, although
this skew was partially corrected by separate prioritisa-
tion analysis in the second survey. Lastly, it is possible
that the most severely affected patients were under-
represented within this PSP due to their limited ability
to participate, both during the survey and the final work-
shop stages.
In the future, we encourage researchers, funding bod-
ies and other stakeholders to promote and use the top
10 research priorities in guiding their work. The adopted
approach for this project enabled us to identify the un-
certainties relevant to those who should benefit the most
from the research on rare metabolic bone diseases – the
patients. Hence, we hope that the findings of this PSP
will minimise the research mismatch [4, 5] and maxi-
mise the impact of future research in improving therapy.
Conclusions
This JLA PSP has identified the top 10 research prior-
ities most relevant to adult patients with rare musculo-
skeletal disease, their carers and healthcare professionals.
It is the first to do so for any metabolic bone disease
and one of the few addressing rare disease, where little
high-quality research exists, and funding is especially
limited. Hence, the top 10 priorities should serve as
Fig. 2 The top 10 research priorities of the rare musculoskeletal diseases in adults PSP
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guidelines for future research work on rare musculoskel-
etal disease, maximising patient benefit and reducing
funding waste on projects that are less urgent.
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